This aligns with the findings of the DAPA-HF trial, which also demonstrated significant reductions in cardiovascular deaths and worsening HF events with the use of dapagliflozin, another SGLT2 inhibitor [17]. Here, SLC5A2 is linked to hydrops fetalis.